Society


Posts filtered by tags: Merus[x]


 

ASG LegalTech Adds Another Practice Management Acquisition To Its Growing Portfolio

Three weeks after investment firm Alpine SG merged two practice-management companies it acquired, PracticePanther and Bill4Time, to create a unified legal technology business, ASG LegalTech, the firm is today announcing the acquisition of another practice management company, Merus Inc., developer of MerusCase. Founded in 2008, MerusCase is a cloud-based case management platform designed as a comprehensive and fully integrated system suitable for small- to medium-sized firms. The company says its...
Tags: Law, Uncategorized, Johnny, Shane, HIPAA, ASG, Bob Ambrogi, PracticePanther, Merus, Soumya, Soumya Nettimi, Nettimi, Alpine SG, ASG LegalTech, Bill4Time, MerusCase


ASG LegalTech Adds Another Practice Management Acquisition To Its Growing Portfolio

Three weeks after investment firm Alpine SG merged two practice-management companies it acquired, PracticePanther and Bill4Time, to create a unified legal technology business, ASG LegalTech, the firm is today announcing the acquisition of another practice management company, Merus Inc., developer of MerusCase. Founded in 2008, MerusCase is a cloud-based case management platform designed as a comprehensive and fully integrated system suitable for small- to medium-sized firms. The company says its...
Tags: Law, Uncategorized, Johnny, Shane, HIPAA, ASG, PracticePanther, Merus, Soumya, Soumya Nettimi, Nettimi, Alpine SG, ASG LegalTech, Bill4Time, MerusCase, Merus Inc


Webinar today on Inequitable Conduct Post-Regeneron

By David Hricik The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled “Inequitable Conduct After Regeneron: What Litigators, Patent Prosecutors, and Patent Owners Need to Know” on January 10, 2019 from 2:00 to 3:00 pm (ET).  Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff LLP, and Rohit Singla, Munger of Tolles & Olson LLP and I will discuss the significant ongoing impact of the 2017 Federal Circuit decision in Regeneron v. Merus, which found a patent une...
Tags: Law, Ethics, Federal Circuit, Regeneron, Kevin Noonan, McDonnell Boehnen Hulbert Berghoff LLP, Intellectual Property Owners Association IPO, David Hricik, Merus, Rohit Singla Munger, Tolles Olson LLP


Supreme Court Denies Certiorari in Regeneron Pharmaceuticals v. Merus

By Kevin E. Noonan -- Last week, the Supreme Court denied certiorari to Regeneron Pharmaceuticals in its appeal of the Federal Circuit's decision in Regeneron Pharmaceuticals v. Merus that affirmed the District Court's decision that the claims of Regeneron's patent-in-suit were unenforceable due to inequitable conduct in the patent's procurement. In so doing the Court passed up the opportunity to consider whether the split panel's decision was consistent with the Federal Circuit's own inequitabl...
Tags: Supreme Court, Law, Court, Fed, District Court, Becton Dickinson, Federal Circuit, Regeneron, Regeneron Pharmaceuticals, Therasense Inc, Patent Docs, Kevin E Noonan, Inequitable Conduct, Merus, Supreme Court Denies Certiorari


Rendering Patent Unenforceable Due to Litigation Misconduct

Regeneron Pharmaceuticals, Inc., Petitioner v. Merus N.V., SCT Docket No. No. 17-1616 (On petition for writ of certiorari 2018). Question presented: Whether a patent right can be fully extinguished based on misconduct committed by the patentee’s counsel during federal district court litigation to enforce the patent right. Petition. The patentee here argues that inequitable conduct should be limited to situations involving “misconduct before the Patent Office in obtaining a patent.” In this case,...
Tags: Law, Patent, Patent Office, Federal Circuit, Regeneron, Regeneron Pharmaceuticals Inc, Merus, Merus N, Regeneron Pharmaceuticals Inc Petitioner, En Banc Chances Rise Inequitable Conduct


Regeneron v. Merus: Sui Generis or a Regener-ating Fact Pattern?

Guest Post by Brian Landry and Justin Crotty of Saul Ewing in Boston On December 26, 2017, the U.S. Court of Appeals for the Federal Circuit issued an order denying Regeneron Pharmaceuticals, Inc.’s combined petition for panel rehearing and rehearing en banc of a decision upholding a District Court holding of unenforceability due to inequitable conduct.  Regeneron Pharmaceuticals, Inc. v. Merus N.V., No. 2016-1346 (Fed. Cir. Dec. 26, 2017).  Of concern to many patent prosecutors, the District Co...
Tags: Law, Boston, Patent, Jones, Murphy, District Court, Federal Circuit, U S Court of Appeals for the Federal Circuit, Regeneron, Regeneron Pharmaceuticals Inc, Saul Ewing, Fed Cir, Inequitable Conduct, Merus, Merus N, Brian Landry


Regeneron v. Merus: En Banc Chances Rise

by Dennis Crouch Prof. Hricik and I have both previously written about the Regeneron inequitable conduct decision.  The following short summary comes from Hricik: [The] district court … held that people substantively involved in prosecution of the ‘018 Patent knew of but-for material references, which were not disclosed.  Although the district court had intended to hold a separate trial on intent to deceive, instead it held that the patentee’s discovery abuses (and other apparent misconduct) war...
Tags: Law, Chicago, Uspto, Patent, Fed, Newman, PTO, Federal Circuit, Regeneron, Regeneron Pharmaceuticals Inc, Kevin Noonan, Patent and Trademark Office PTO, Inequitable Conduct, Merus, Merus N, Dennis Crouch Prof Hricik


Important Inequitable Conduct Case: Hybrid Prosecution/Litigation Misconduct

Regeneron Pharmaceuticals, Inc. v. Merus N.V. (Federal Circuit 2017) In a split decision, the Federal Circuit has affirmed a S.D.N.Y. judgment – finding Regeneron’s U.S. Patent No. 8,502,018 unenforceable based upon inequitable conduct during prosecution.   The inequitable conduct allegation here follows the typical pattern – the patentee failed to submit four relevant prior art references.  The majority opinion was penned by Chief Judge Prost and joined by Judge Wallach.  Judge Newman wrote in ...
Tags: Law, Patent, Newman, Murphy, PTO, Appellant, Federal Circuit, Wallach, Prost, Regeneron, Regeneron Pharmaceuticals Inc, Merus, Merus N V Federal Circuit


Regeneron Pharmaceuticals, Inc. v. Merus N.V. (Fed. Cir. 2017)

[The author of this article, along with Patent Docs authors Andrew Williams and Donald Zuhn, and MBHB attorneys Jeff Armstrong, Aaron Gin, Jim Lovsin, and Jeremy Noe, filed an amicus curiae brief in support of Appellant Regeneron Pharmaceuticals, Inc. and vacatur. Ed.] By Kevin E. Noonan -- In a decision that took an inordinately long time to arrive (oral argument was held in mid-January), the Federal Circuit in Regeneron Pharmaceuticals v. Merus today affirmed the District Court's decision that...
Tags: Law, District Court, Federal Circuit, Regeneron, Regeneron Pharmaceuticals Inc, Andrew Williams, Patent Docs, Kevin E Noonan, Donald Zuhn, MBHB, Inequitable Conduct, Merus N V Fed, Jeff Armstrong Aaron Gin Jim Lovsin, Jeremy Noe, Appellant Regeneron Pharmaceuticals Inc, Federal Circuit in Regeneron Pharmaceuticals



Filters
January - 2019
MoTuWeThFrSaSu
 123456
78910111213
14151617181920
21222324252627
28293031   
February - 2019
MoTuWeThFrSaSu
    123
45678910
11121314151617
18192021222324
25262728   
March - 2019
MoTuWeThFrSaSu
    123
45678910
11121314151617
18192021222324
25262728293031